-
-
Gold Medal.
Congratulations!
-
VPearce reacted to a post in a topic: Applied Blood Group Serology, 4th edition,by Issitt and Anstee
-
VPearce reacted to a post in a topic: Applied Blood Group Serology, 4th edition,by Issitt and Anstee
-
-
Neonatal Exchange Transfusion
We have our blood supplier manufacture the product for us.
-
Pooling platelets
Currently we have random donor platelets that we may pool into a single product. These random platelets are bacterial tested by our current blood supplier. We use 6 random donor platelets to equal a single apheresis product, but I've seen 4 randoms used at times to match an apheresis product. This pooled product is used when apheresis product inventory is low, or when there is a suspicion of platelet refractoriness. We usually see patients who do not display a "bump" with an apheresis product. We will switch to a pooled product to see if we see a "bump". If yes, we send specimen for platelet antibody screen testing. If positive, we request a crossmatch compatible platelet product for patient.
-
COMPARISON OF BLOOD UTILIZATION
There are companies out there, like Premier, which examine your blood usage and compare you to other facilities similar in size and complexity. Often, the hospital is required to submit data and then Premier does their magic and generates reports based on what others in your peer group have also submitted. I must caution you though that matching complexity can be a challenge.
-
Ortho Gel 0.8% Screening Cells VSS548
We had a problem with lot VSS547 doing the same thing. When we run into problems like this, we perform a DAT on the cell to see if this is what is causing the problem. If yes, contact ORTHO and they will replace the lot. I can tell you this is the most common cause. Unfortunately, this wasn't the case for VSS547. We ended up tossing our opened vials and replacing with unopened sets. I suspect bacterial contamination.
-
Ortho 0.8% Surgiscreen Inconclusive Reactions (VSS517)
We found that cell 2 had a positive DAT. We contacted ORTHO who is aware of the problem. They replaced our shipment.
-
Document Control System
We use MasterControl for our documentation program. Although initially there is much thinking/work in creating the right route structure, it has served us well.
-
Which antibodies would you ignore first and last and in between in an emergent transfusion and why?
Take a look at article Transfusion 2002 42: p. 1435. The discussion is related to WAA patients, but you may find the information helpful. In our institution we would drop S, then Fy(a).